Mylan (MYL, $23.68) revenue misses estimates, even as earnings surpass expectations
Mylan’s first-quarter revenue fell short of analysts' expectations.
The pharmaceutical company reported revenue of $2.5 billion, falling behind analysts’ expectations of $2.69 billion. Revenue was -7% lower compared to the year-ago period. Revenue from its U.S. business declined -6%.
However, the pharmaceutical company’s adjusted earnings came in at 82 cents per share, beating analysts’ estimates of 79 cents per share.
For the full year, the company projects earnings to range between $3.80 and $4.80 per share, while predicting a revenue range of $11.5 billion to $12.5 billion. Analysts are expecting earnings of $4.41 per share on revenue of $11.96 billion.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Advertisement
General Information
a manufacturer of pharmaceuticals
Industry NotClassified
Advertisement